+44 (0)1865 595230
0 Items

References

There is no better testament to the quality of our products than when they are included in peer-reviewed scientific publications. We aim to collate all of the references that we’re aware of below, but if you know of any others please do let us know.

If you publish your own work and include a reference to one of our products we will be pleased to offer you a 25% discount on your next order – just contact us for details.

Adenovirus

Ad-GFP (available on request)

Mlcochova P et al (2017). DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages. EMBO J. Oct 30. pii: e201796880. PMID: 29084722

Mo S et al (2015). Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours. J Control Release. 210:10-8. PMID: 25975831

Ad-LUC (available on request)

Myers R et al. (2018). Ultrasound-mediated cavitation does not decrease the activity of small molecule, antibody or viral-based medicines. Int J Nanomedicine. Jan 10;13:337-349. PMID: 9391793

Ad5-MyoD (available on request)

Zaric M et al (2017). Long-lived tissue resident HIV-1 specific memory CD8+ T cells are generated by skin immunization with live virus vectored microneedle arrays. J Control Release. Dec 28;268:166-175. PMID: 29056444

Toh ZY et al (2016). Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies. PLoS One. Jan 8;11(1):e0145620. PMID: 26745801

Greer K et al (2015). Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient. Mol Genet Genomic Med. 3(4):320-6. PMID: 26247048

Greer KL et al (2014). Targeted exon skipping to correct exon duplications in the dystrophin gene. Mol Ther Nucleic Acids. Mar 18;3:e155. PMID: 24643206

Fletcher S et al (2013). Antisense suppression of donor splice site mutations in the dystrophin gene transcript. Mol Genet Genomic Med. Sep;1(3):162-73. PMID: 24498612

Fletcher S et al (2012). Targeted exon skipping to address “leaky” mutations in the dystrophin gene. Mol Ther Nucleic Acids. Oct 16;1:e48. PMID: 23344648

Adkin CF et al (2012). Multiple exon skipping strategies to by-pass dystrophin mutations. Neuromuscul Disord. Apr;22(4):297-305. PMID: 22182525

Adenovirus contract manufacturing

Becker PD et al (2015). Skin vaccination with live virus vectored microneedle arrays induce long lived CD8(+) T cell memory. Vaccine. Sep 8;33(37):4691-8. PMID: 25917679

O’Brien LM et al (2014). Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse. Virology. Mar;452-453:324-33. PMID: 24461913

Bachy V et al (2013). Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci U S A. Feb 19;110(8):3041-6. PMID: 23386724

Adenoviruses 3, 5 and 11 (available on request)

Dyer A et al (2016). Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators. Mol Ther Oncolytics. Dec 10;4:18-30. PMID: 28345021

Thoma C et al (2013). Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy. Virology. Dec;447(1-2):74-83. PMID: 24210101

Bordetella pertussis

Pertussis toxin

Doronin VB et al (2016). Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein. J Cell Mol Med. Jan;20(1):81-94. PMID: 26493273

Salcedo-Rivillas C et al (2014). Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae. Clin Vaccine Immunol. Jul;21(7):972-81. PMID: 24807055

Clostridium Difficile

C Diff toxin A and B

Immunology and Microbiology » “Clostridium Difficile – A Comprehensive Overview”, book edited by Shymaa Enany, ISBN 978-953-51-3428-2, Print ISBN 978-953-51-3427-5, Published: September 27, 2017 under CC BY 3.0 license. © The Author(s). Chapter 5: Assays for Measuring C. difficile Toxin Activity and Inhibition in Mammalian Cells. Cox MA et al . DOI: 10.5772/68127

Kuehne SA et al (2017). Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin. J Antimicrob Chemother. Dec 15. doi: 10.1093/jac/dkx486. [Epub ahead of print]. PMID: 29253242

Dhillon HS et al (2016). Homogeneous and digital proximity ligation assays for the detection of Clostridium difficile toxins A and B. Biomol Detect Quantif. Aug 31;10:2-8. PMID: 27990343

Zhao X et al (2016). Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection. Bioanalysis. Apr;8(7):611-23. PMID: 26964649

Bézay N et al (2016). Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. May 17;34(23):2585-92. PMID: 27079932

Huang JH et al (2015). Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci. Aug 7;22:65. PMID: 26245825

Hernandez LD et al (2017). Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab. J Mol Biol. Apr 7;429(7):1030-1044. PMID: 28232034

Orth P et al (2014). Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. Jun 27;289(26):18008-21. PMID: 24821719

C. Diff toxoid A

Huang JH et al (2015). Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A. PLoS One. Aug 13;10(8):e0135045. PMID: 26271033

C. Diff toxin A ribotype 027

Tian JH et al (2017). Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models. Vaccine. Jul 24;35(33):4079-4087. PMID: 28669616

C. Diff toxin A ribotype 078

Secore S et al (2017). Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains. PLoS One. Jan26;12(1):e0170640. PMID: 28125650

CMV

CMV-CL

Albayati Z et al (2017). The Influence of Cytomegalovirus on Expression of HLA-G and its Ligand KIR2DL4 by Human Peripheral Blood Leucocyte Subsets. Scand J Immunol. Nov;86(5):396-407. PMID: 28817184

Huang TS et al (2014). No evidence of association between human cytomegalovirus infection and papillary thyroid cancer. World J Surg Oncol. Feb 21;12:41. PMID: 24559116

Nabatanzi R et al (2014). Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort. Immunol Lett. Dec;162(2 Pt B):264-72. PMID: 25263953

CMV-Pentamer

John S et al. (2018). Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018 Mar 14;36(12):1689-1699. PMID: 29456015

 

Dengue Virus

NS1 proteins - all serotypes (DENVX4-NS1)

Badolato-Corrêa J et al (2018) Human T cell responses to Dengue and Zika virus infection compared to Dengue/Zika coinfection. Immun Inflamm Dis. Jun;6(2):194-206. PMID: 29282904

Nascimento EJM et al (2018). Development of antibody biomarkers of long term and recent dengue virus infections. J Virol Methods. Apr 21;257:62-68. PMID: 29684416

Nascimento EJM et al. (2018). Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. Mar 19;257:48-57. PMID: 2956751

Rönnberg B et al (2017). Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections. Med Microbiol Immunol. Oct;206(5):383-401. PMID: 28852878

Glasner DR et al (2017). Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components. PLoS Pathog. Nov 9;13(11):e1006673. PMID: 29121099

Rogers TF et al (2017). Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. Sci Immunol. Aug 18;2(14). PMID: 28821561

Puerta-Guardo H et al (2016). Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability. PLoS Pathog. Jul 14;12(7):e1005738. PMID: 27416066

Beatty PR et al (2015). Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med. Sep 9;7(304):304ra141. PMID: 26355030

Gelanew T et al (2015). Development and characterization of mouse monoclonal antibodies against monomeric dengue virus non-structural glycoprotein 1 (NS1). J Virol Methods. Sep 15;222:214-23. PMID: 26070890

Dengue Virus serotype 2 NS1 protein (DENV2-NS1)

Chen HR et al. (2018). Macrophage migration inhibitory factor is critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability. PLoS Pathog. Apr 27;14(4):e1007033. PMID: 29702687

Tam JO et al (2017). A comparison of nanoparticle-antibody conjugation strategies in sandwich immunoassays. J Immunoassay Immunochem. 38(4):355-377. PMID: 27982728

Chen HR et al (2016). Dengue Virus Non-structural Protein 1 Induces Vascular Leakage through Macrophage Migration Inhibitory Factor and Autophagy. PLoS Negl Trop Dis. Jul 13;10(7):e0004828. PMID: 27409803

Conde JN, et al (2016). Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins. J Virol. Oct 14;90(21):9570-9581. PMID: 27512066

Dengue Virus serotype 4 NS1 protein (DENV4-NS1)

Heringer M et al (2017). Dengue type 4 in Rio de Janeiro, Brazil: case characterization following its introduction in an endemic region. BMC Infect Dis. Jun 9;17(1):410. PMID: 28599640

Dengue Virus-like particles (DENV*-VLP)

Aurelie Deliot et al (2017) Visualization of Dengue virus like particles interacting with antibodies. The 16th European Microscopy Congress, Lyon, France.

http://emc-proceedings.com/abstract/visualization-of-dengue-virus-like-particles-interacting-with-antibodies/

Metz SW et al. (2018). Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol J. 2018 Apr 2;15(1):60. PMID: 29609659

Goldman ER et al (2017). Bglbrick strategy for the construction of single domain antibody fusions. Heliyon. Dec 28;3(12):e00474. PMID: 29322100

Lecouturier V et al. (2018). Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes. Vaccine. Apr 26. pii: S0264-410X(18)30562-0. PMID: 29706291

Usutu Virus

Usutu virus NS1 protein

Nascimento EJM et al. (2018). Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. 2018 Mar 19;257:48-57. PMID: 2956751

West Nile Virus

WNV NS1 protein

Nascimento EJM et al. (2018). Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. 2018 Mar 19;257:48-57. PMID: 2956751

Tagliabue G et al (2017). A label-free immunoassay for Flavivirus detection by the Reflective Phantom Interface technology. Biochem Biophys Res Commun. Oct 28;492(4):558-564. PMID: 28501619

Glasner DR et al (2017). Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components. PLoS Pathog. Nov 9;13(11):e1006673. PMID: 29121099

Conde JN et al (2016). Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins. J Virol. Oct 14;90(21):9570-9581. PMID: 27512066

Puerta-Guardo H et al (2016). Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability. PLoS Pathog. Jul 14;12(7):e1005738. PMID: 27416066

Beatty PR et al (2015). Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med. Sep 9;7(304):304ra141. PMID: 26355030

Yellow Fever Virus

YFV NS1 protein

Nascimento EJM et al. (2018). Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. 2018 Mar 19;257:48-57. PMID: 2956751

Yen CW et al (2015). Multicolored silver nanoparticles for multiplexed disease diagnostics: distinguishing dengue, yellow fever, and Ebola viruses. Lab Chip.7;15(7):1638-41. PMID: 25672590

Zika Virus

ZIKV Envelope protein

Wen J et al (2017). Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge. Nat Commun. Nov 13;8(1):1459. PMID: 29129917

ZIKV NS1 protein

Balmaseda A et al. (2018). Comparison of four serological methods and two RT-PCR assays for diagnosis and surveillance of Zika. J Clin Microbiol. Jan 5. pii: JCM.01785-17. doi: 10.1128/JCM.01785-17. [Epub ahead of print]. PMID: 29305550

Theillet G et al. (2018). Laser-cut paper-based device for the detection of dengue non-structural NS1 protein and specific IgM in human samples. Arch Virol. Mar 10. doi: 10.1007/s00705-018-3776-z. [Epub ahead of print] PMID: 29525973

Nascimento EJM et al. (2018). Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. 2018 Mar 19;257:48-57. PMID: 2956751

Afsahi S et al (2018). Novel graphene-based biosensor for early detection of Zika virus infection. Biosens Bioelectron. 100:85-88. PMID: 28865242

Balmaseda A et al (2017). Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proc Natl Acad Sci U S A. Aug 1;114(31):8384-8389. PMID: 28716913

Zhang B et al (2017). Diagnosis of Zika virus infection on a nanotechnology platform. Nat Med. May;23(5):548-550. PMID: 28263312

Bedin F et al (2017). Paper-based point-of-care testing for cost-effective diagnosis of acute flavivirus infections. J Med Virol. Sep;89(9):1520-1527. PMID: 28295400

Conde JN et al (2016). Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins. J Virol. Oct 14;90(21):9570-9581. PMID: 27512066

Get in Touch With Us

The Native Antigen Company sometimes likes to send exclusive information and offers to our customers, please let us know if you are happy to receive these

5 + 2 =

Customer Feedback